ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Triple Negative Breast Cancer trials near New Haven, CT, USA:

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 9 other locations

the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Enzalutamide
Behavioral: assessment

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Hartford, Connecticut, United States and 11 other locations

a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast...

Active, not recruiting
Breast Cancer
Radiation: Radiotherapy
Drug: Rucaparib

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Norwalk, Connecticut, United States and 7 other locations

maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast...

Active, not recruiting
Relapsed/refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Drug: OTS167PO

Phase 1

OncoTherapy Science

Norwalk, Connecticut, United States and 4 other locations

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-n ...

Active, not recruiting
Breast Cancer
Drug: Carboplatin
Drug: Nivolumab

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 9 other locations

before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers. The study drugs could shrink cancer, bu...

Active, not recruiting
Breast Cancer
Drug: Olaparib
Drug: Pembrolizumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Danbury, Connecticut, United States and 176 other locations

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effec...

Enrolling
Breast Cancer
Metastatic Triple-Negative Breast Cancer
Drug: Eribulin
Other: Placebo

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 7 other locations

levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple...

Enrolling
Locally Advanced Breast Cancer
Metastatic Triple Negative Breast Cancers
Drug: BNT327 Equivalent Q3W Dose
Drug: BNT327 Dose Level 1 (DL2)

Phase 2

BioNTech
BioNTech

New Haven, Connecticut, United States and 63 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

New Haven, Connecticut, United States and 225 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems